skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Lapatinib: new opportunities for management of breast cancer

Review

(2266) Views  (716) Full article downloads

Authors: Julia Liao, Michelle Gallas, Mark Pegram, et al

Published Date November 2010 Volume 2010:2 Pages 79 - 91
DOI: http://dx.doi.org/10.2147/BCTT.S5929

Julia Liao1, Michelle Gallas1, Mark Pegram1,2,3, Joyce Slingerland1,2,3,4
1Braman Family Breast Cancer Institute, 2Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, 3Departments of Medicine, 4Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA

Abstract: Approximately 20% of new diagnosed breast cancers overexpress the human epidermal growth factor receptor 2 (EGFR2), also known as erythroblastic leukemia viral oncogene homolog 2 (ERBB2) protein, as a consequence of ERBB2 gene amplification, resulting in a poor prognosis. Clinical outcome can be substantially improved by ERBB2-targeted therapy. Lapatinib is a potent, orally bioavailable small molecule that reversibly and selectively inhibits epidermal growth factor receptor (EGFR1 or ERBB1) and ERBB2 tyrosine kinases. Lapatinib binds the adenosine triphosphate-binding site of the receptor’s intracellular domain to inhibit tumor cell growth. This review summarizes the pharmacology, pharmacokinetics, efficacy, and tolerability of lapatinib, and reviews both Food and Drug Administration-approved and investigational uses of lapatinib in breast cancer therapy. The drug is generally well tolerated in patients, with diarrhea and rashes being the most common (usually mild or moderate) adverse effects. Unlike trastuzumab, lapatinib has infrequent adverse effects on cardiac function. Lapatinib has substantial activity for advanced ERBB2-positive breast cancer, particularly in combination with capecitabine, following progression after anthracyclines, taxanes, and trastuzumab. Lapatinib combined with capecitabine yielded significant improvements in time to progression and response rate compared with capecitabine alone. This drug can also be combined with letrozole for the treatment of postmenopausal women with ERBB2-positive breast cancer, for whom hormonal therapy is indicated. Lapatinib has shown early promise in treatment of central nervous system metastasis and is being further evaluated in various clinical settings.

Keywords: lapatinib, trastuzumab, ERBB family, ERBB2, breast cancer, capecitabine, letrozole






Readers of this article also read:

New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells
Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer
Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review
Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane
Role of trastuzumab in the management of HER2-positive metastatic breast cancer
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
Potential clinical applications of halichondrins in breast cancer and other neoplasms
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University